1-6 of 6
Leslie Smetzer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

Toshio Shimizu, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew W. Rasco, Lon S. Smith, Shelly Gunn, Leslie Smetzer, Theresa A. Mays, Brianne Kaiser, Michael J. Wick, Cathy Alvarez, Aracely Cavazos, Gina L. Mangold, Amita Patnaik
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (8): 2316–2325.
https://doi.org/10.1158/1078-0432.CCR-11-2381
Published: 16 April 2012
View article titled, The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
Open the PDF for The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer

Anthony W. Tolcher, John Kuhn, Garry Schwartz, Amita Patnaik, Lisa A. Hammond, Ian Thompson, Howard Fingert, David Bushnell, Shazli Malik, Jeffrey Kreisberg, Elzbieta Izbicka, Leslie Smetzer, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (15): 5048–5057.
https://doi.org/10.1158/1078-0432.CCR-03-0701
Published: 05 August 2004
View article titled, A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer
Open the PDF for A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer in another window
Journal Articles

A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies

Bahram Forouzesh, Chris H. Takimoto, Andrew Goetz, Sami Diab, Lisa A. Hammond, Leslie Smetzer, Garry Schwartz, Robert Gazak, John T. Callaghan, Daniel D. Von Hoff, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (15): 5540–5549.
Published: 03 December 2003
View article titled, A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies in another window
Journal Articles

A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies

Mitchell A. Garrison, Lisa A. Hammond, Charles E. Geyer, Jr., Garry Schwartz, Anthony W. Tolcher, Leslie Smetzer, Jose A. Figueroa, Murray Ducharme, John Coyle, Chris H. Takimoto, Robert L. De Jager, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (7): 2527–2537.
Published: 01 July 2003
View article titled, A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies in another window
Journal Articles

A Phase I and Pharmacokinetic Study of 1843U89, a Noncompetitive Inhibitor of Thymidylate Synthase, in Patients with Advanced Solid Malignancies

Garry Schwartz, Thomas R. Johnson, Andrew Goetz, Howard Burris, Leslie Smetzer, Thomas Lampkin, Jeffrey Sailstad, John A. Hohneker, Daniel D. Von Hoff, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (7): 1901–1911.
Published: 01 July 2001
View article titled, A Phase I and Pharmacokinetic Study of 1843U89, a Noncompetitive Inhibitor of Thymidylate Synthase, in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I and Pharmacokinetic Study of 1843U89, a Noncompetitive Inhibitor of Thymidylate Synthase, in Patients with Advanced Solid Malignancies in another window
Journal Articles

A Phase I and Pharmacokinetic Study of the Mitochondrial-specific Rhodacyanine Dye Analog MKT 077

Carolyn D. Britten, Eric K. Rowinsky, Sharyn D. Baker, Geoffrey R. Weiss, Lon Smith, Joseph Stephenson, Mace Rothenberg, Leslie Smetzer, Jeffrey Cramer, William Collins, Daniel D. Von Hoff, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (1): 42–49.
Published: 01 January 2000
View article titled, A Phase I and Pharmacokinetic Study of the Mitochondrial-specific Rhodacyanine Dye Analog MKT 077
Open the PDF for A Phase I and Pharmacokinetic Study of the Mitochondrial-specific Rhodacyanine Dye Analog MKT 077 in another window